CoChat
Sign Up
Cited by 147Herpesvirus Infections and TreatmentsCytomegalovirus and herpesvirus researchCervical Cancer and HPV Research

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Oral Famciclovir for the Suppression of Recurrent Genital Herpes<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>

Diaz-Mitoma, Francisco·1998·JAMA
DOI 10.1001/jama.280.10.887
Open this paper in CoChat — free account

Abstract

CONTEXT: Recurrent genital herpes simplex virus (HSV) may be treated episodically, but this may not be sufficient for patients with frequent recurrences. OBJECTIVE: To determine the efficacy and safety of famciclovir in the suppression of recurrent genital HSV infection. DESIGN: A randomized, double-blind, placebo-controlled, parallel-group study. SETTING: Thirty university, hospital, or private outpatient referral centers in Canada and Europe. PATIENTS: A total of 455 patients (223 men, 232 women) aged 18 years or older with a history of 6 or more episodes of genital herpes during 12 of the most recent 24 months, in the absence of suppressive therapy, received study medication. INTERVENTION: Oral famciclovir, 125 mg or 250 mg 3 times daily or 250 mg twice daily, or placebo for 52 weeks. MAIN OUTCOME MEASURES: Time to the first recurrence of genital HSV infection; the proportion of patients remaining free of HSV recurrence at 6 months; frequency of adverse events. RESULTS: In an intent-to-treat analysis, famciclovir significantly delayed the time to the first recurrence of genital herpes at all dose regimens (hazard ratios, 2.9-3.3; P<.001); median time to recurrence for famciclovir recipients was 222 to 336 days compared with 47 days for placebo recipients. The proportion of patients remaining free of HSV recurrence was approximately 3 times higher in famciclovir recipients (79%-86%) than in placebo recipients (27%) at 6 months (relative risks, 2.9-3.1; P<.001); efficacy was maintained at 12 months. Famciclovir was well tolerated with an adverse experience profile comparable to placebo. CONCLUSIONS: Oral famciclovir (125 mg or 250 mg 3 times daily or 250 mg twice daily) is an effective, well-tolerated treatment for the suppression of genital HSV infection in patients with frequent recurrences.

Overview

Integrity signals

Registry

Crossref · 10.1001/jama.280.10.887

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 24 references

Cited by

Sorted by citations

Items 101–147 of 147

Related

See all

Metadata

Authors
Diaz-Mitoma, F.
Venue
JAMA
Publisher
American Medical Association (AMA)
Published
1998-09-09
Volume
280
Issue
10
Pages
887
ISSN
  • 0002-9955 (ISSN-L)
  • 0098-7484
DOI
10.1001/jama.280.10.887
OpenAlex
W2083993202
Cited by
147
References
24
Citations by year
2026: 3 · 2025: 4 · 2023: 4 · 2022: 2 · 2021: 7 · 2019: 2 · 2017: 1 · 2016: 4 · 2015: 3 · 2014: 3 · 2013: 7 · 2012: 3
FWCI
9.26
Type
journal article
Language
en
Open access
closed
Locations
  • JAMA (publishedVersion)
  • PubMed (publishedVersion)
Funders
Háskóli Íslands
Topics
  • Health Sciences › Medicine › Infectious Diseases › Herpesvirus Infections and Treatments
  • Health Sciences › Medicine › Epidemiology › Cytomegalovirus and herpesvirus research
  • Health Sciences › Medicine › Epidemiology › Cervical Cancer and HPV Research
Keywords
famciclovir, recurrent genital herpes, herpes simplex virus, suppressive therapy, antiviral therapy, time to recurrence, adverse events, dose comparison
MeSH terms
Famciclovir, Administration, Oral, Adult, Aged, Antiviral Agents, Double-Blind Method, Female, Herpes Genitalis, Humans, Male, Middle Aged, Recurrence, 2-Aminopurine, Proportional Hazards Models, Statistics, Nonparametric

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review